Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib

  • Authors:
    • Tetsuo Fujita
    • Ken‑Ichi Tabata
    • Daisuke Ishii
    • Kazumasa Matsumoto
    • Kazunari Yoshida
    • Masatsugu Iwamura
  • View Affiliations

  • Published online on: March 20, 2017     https://doi.org/10.3892/mco.2017.1201
  • Pages:691-696
0

Abstract

C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib. A total of 56 consecutive patients with advanced RCC treated with sunitinib between December, 2008 and December, 2012 were enrolled in the present study. The patients were retrospectively divided into 3 cohorts according to pretreatment serum CRP level and CRP kinetics: i) Normal CRP cohort (pretreatment CRP ≤0.30 mg/dl); ii) normalized CRP cohort (pretreatment CRP >0.30 mg/dl that normalized within 2 cycles of treatment); and iii) non-normalized CRP cohort (pretreatment CRP >0.30 mg/dl that did not normalize after sunitinib initiation). Disease control rate, progression‑free survival and overall survival times were compared for the 3 cohorts. The normal (n=17, 30.4%) and the normalized (n=8, 14.3%) CRP cohorts exhibited significantly better disease control rates compared with the non‑normalized CRP cohort (n=31, 55.4%; P<0.0001 and P=0.0445, respectively). The normal CRP cohort exhibited significantly longer progression‑free survival compared with the non‑normalized CRP cohort (P=0.0050). The normal and normalized CRP cohorts exhibited significantly longer overall survival compared with the non‑normalized CRP cohort (P=0.0005 and 0.0466, respectively). Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib.

Related Articles

Journal Cover

May 2017
Volume 6 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fujita, T., Tabata, K., Ishii, D., Matsumoto, K., Yoshida, K., & Iwamura, M. (2017). Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib. Molecular and Clinical Oncology, 6, 691-696. https://doi.org/10.3892/mco.2017.1201
MLA
Fujita, T., Tabata, K., Ishii, D., Matsumoto, K., Yoshida, K., Iwamura, M."Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib". Molecular and Clinical Oncology 6.5 (2017): 691-696.
Chicago
Fujita, T., Tabata, K., Ishii, D., Matsumoto, K., Yoshida, K., Iwamura, M."Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib". Molecular and Clinical Oncology 6, no. 5 (2017): 691-696. https://doi.org/10.3892/mco.2017.1201